# US 2026/0083715 A1 · Composition for enhancing immunity containing amide-based compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083715 A1
- Document ID: US20260083715A1
- Status: Published application
- Kind: A1
- Application number: 19/335,570
- Filed: 2025-09-22
- Published: 2026-03-26
- Earliest claimed: 2024-09-25
- Assignees: Amorepacific Corporation
- Applicants: Amorepacific Corporation
- Inventors: Eun Jeong CHOI; Geunhyuk JANG; Hyunjung CHOI; Hyoung June KIM; Wonseok PARK; Heungsoo BAEK; Jaewon YOU
- Web page: https://patentgrep.com/patent/US20260083715A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61P 37/04: Immunostimulants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present specification relates to a composition containing a novel amide-based compound derived from an amino acid structure such as valine, leucine, phenylalanine, proline, or pipecolic acid, and the composition can exhibit an immune-enhancing effect by activating the phagocytosis of macrophages, which aids in removing pathogenic bacteria as an important part of the human immune system.

## Claims

### Claim 1

A method for enhancing immunity, the method comprising administering an effective amount of a composition containing, as an active ingredient, a compound represented by the following Chemical Formula 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof to a subject in need thereof:
wherein, in Chemical Formula 1,
X is represented by any one of the following Chemical Formulae 1-1 to 1-5,
in Chemical Formula 1-1,
Ar is phenyl unsubstituted or substituted with one to three R1,
R1 is hydrogen, a phenyl group, a C1-C4 alkoxy group, a C1-C4 alkyl group, a fluoro group, an adamantane group, an acetylamino group, or a hydroxyiminoethyl group,
when there are more than one R1 residue, all R1 residues are the same as each other,
in Chemical Formula 1-2,
Ar is phenyl substituted with one R2,
R2 is a C1-C4 alkyl group, a C1-C4 alkoxy group, an adamantane group, an acetyl group, or an acetylamino group,
in Chemical Formula 1-3,
Ar is phenyl substituted with one to three R3 or unsubstituted naphthalene,
R3 is hydrogen, or a C1-C4 alkyl group or a phenyl group,
when there are more than one R3 residue, all R3 residues are the same as each other,
in Chemical Formula 1-4,
Ar is phenyl unsubstituted or substituted with one to three R4,
R4 is hydrogen, a phenyl group, a C1-C4 alkyl group, or a C1-C4 alkoxy group,
when there are more than one R4 residue, all R4 residues are the same as each other,
in Chemical Formula 1-5,
Ar is phenyl substituted with one to three R5,
R5 is a C1-C4 alkyl group or a phenyl group, and
when there are more than one R5 residue, all R5 residues are the same as each other.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound represented by Chemical Formula 1 is any one selected from the following compounds:
N-hydroxy-1-(phenylsulfonyl) piperidine-2-carboxamide,
1-([1, l′-biphenyl]-4-ylsulfonyl)-N-hydroxypiperidine-2-carboxamide,
1-((4-(tert-butyl)phenyl) sulfonyl)-N-hydroxypiperidine-2-carboxamide,
1-((4-butoxyphenyl) sulfonyl)-N-hydroxypiperidine-2-carboxamide,
N-hydroxy-1-(mesitylsulfonyl) piperidine-2-carboxamide,
2-([1,1′-biphenyl]-4-sulfonamido)-N-hydroxy-3-phenylpropanamide,
2-((4-(tert-butyl)phenyl) sulfonamido)-N-hydroxy-3-phenylpropanamide,
N-hydroxy-3-phenyl-2-((2,4,6-trimethylphenyl) sulfonamido) propanamide,
N-hydroxy-2-(naphthalene-2-sulfonamido)-3-phenylpropanamide,
2-([1,1′-biphenyl]-4-sulfonamido)-N-hydroxy-4-methylpentanamide,
2-((4-(tert-butyl)phenyl) sulfonamido)-N-hydroxy-4-methylpentanamide,
2-((4-butoxyphenyl) sulfonamido)-N-hydroxy-4-methylpentanamide,
N-hydroxy-4-methyl-2-((2,4,6-trimethylphenyl) sulfonamido) pentanamide,
2-([1,1′-biphenyl]-4-sulfonamido)-N-hydroxy-3-methylbutanamide,
2-((4-(tert-butyl)phenyl) sulfonamido)-N-hydroxy-3-methylbutanamide,
N-hydroxy-3-methyl-2-((2,4,6-trimethylphenyl) sulfonamido) butanamide,
1-((4-fluorophenyl) sulfonyl)-N-hydroxypiperidine-2-carboxamide,
1-((4-((3r,5r,7r)-adamantan-1-yl)phenyl) sulfonyl)-N-hydroxypiperidine-2-carboxamide,
N-hydroxy-1-((4-propylphenyl) sulfonyl) piperidine-2-carboxamide,
1-((4-acetamidophenyl) sulfonyl)-N-hydroxypiperidine-2-carboxamide,
1-((4-(tert-butyl)phenyl) sulfonyl)-N-hydroxypyrrolidine-2-carboxamide,
1-((4-butoxyphenyl) sulfonyl)-N-hydroxypyrrolidine-2-carboxamide,
1-((4-((3r,5r, 7r)-adamantan-1-yl)phenyl) sulfonyl)-N-hydroxypyrrolidine-2-carboxamide,
N-hydroxy-1-((4-propylphenyl) sulfonyl) pyrrolidine-2-carboxamide,
1-((4-acetylphenyl) sulfonyl)-N-hydroxypyrrolidine-2-carboxamide,
N-hydroxy-1-((4-(1-(hydroxyimino)ethyl)phenyl) sulfonyl) piperidine-2-carboxamide,
N-hydroxy-4-methyl-2-(phenylsulfonamido) pentanamide, and
1-((4-acetamidophenyl) sulfonyl)-N-hydroxypyrrolidine-2-carboxamide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound represented by Chemical Formula 1 is any one selected from the following compounds:
N-hydroxy-1-(phenylsulfonyl) piperidine-2-carboxamide,
1-([1,1′-biphenyl]-4-ylsulfonyl)-N-hydroxypiperidine-2-carboxamide,
1-((4-(tert-butyl)phenyl) sulfonyl)-N-hydroxypiperidine-2-carboxamide,
2-([1,1′-biphenyl]-4-sulfonamido)-N-hydroxy-3-phenylpropanamide,
2-((4-(tert-butyl)phenyl) sulfonamido)-N-hydroxy-4-methylpentanamide,
2-((4-butoxyphenyl) sulfonamido)-N-hydroxy-4-methylpentanamide,
N-hydroxy-4-methyl-2-((2,4,6-trimethylphenyl) sulfonamido) pentanamide,
2-([1,1′-biphenyl]-4-sulfonamido)-N-hydroxy-3-methylbutanamide,
1-((4-((3r,5r,7r)-adamantan-1-yl)phenyl) sulfonyl)-N-hydroxypiperidine-2-carboxamide,
1-((4-butoxyphenyl) sulfonyl)-N-hydroxypyrrolidine-2-carboxamide, and
N-hydroxy-1-((4-propylphenyl) sulfonyl) pyrrolidine-2-carboxamide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound represented by Chemical Formula 1 is derived from an amino acid.

### Claim 5 (depends on 1)

The method of claim 1, wherein the enhancing immunity is activating a phagocytosis of macrophages.

### Claim 6 (depends on 1)

The method of claim 1, wherein the enhancing immunity is activating a phagocytosis of macrophages against S. aureus.

### Claim 7 (depends on 1)

The method of claim 1, wherein the enhancing immunity is strengthening the skin barrier.

### Claim 8 (depends on 1)

The method of claim 1, wherein the enhancing immunity is suppressing skin inflammation.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is a cosmetic composition.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is a skin external preparation.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is a food composition.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition is a pharmaceutical composition.

### Claim 13 (depends on 12)

The method of claim 12, wherein the enhancing immunity is preventing, ameliorating, or treating skin inflammation.

### Claim 14 (depends on 1)

The method of claim 1, wherein a content of the active ingredient is 0.01 μM to 100 mM based on a total volume of the composition.

### Claim 15 (depends on 1)

The method of claim 1, wherein a daily application amount of the active ingredient is 1 to 1,000 mg/kg.

### Claim 16 (depends on 1)

The method of claim 1, wherein cells are treated with the active ingredient at a concentration of 1 to 100 μM.
